Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Selcis Biopharma

Selcis Biopharma logo.

Short Chain Fatty Acids (SCFA) are bacterial metabolites produced from fermentation products of dietary fibers and they are major mediators of differentiation, maturation, and activation of intestinal tissue and exerts potent effects on colonic mucosal functions through inhibition of inflammation.

An intestinal dysbiosis can be caused by antibiotics or poor diets, and can lead to decreased levels of SCFA´s in the gut. By improving the nutritional condition of the colon mucosa it may be possible to prevent or even alleviate some diseases. Of the biological active substances formed, the most important is butyric acid which stimulates mucosal cell proliferation, blood flow and oxygen uptake, resulting in a reduced gut permeability and influx of toxic/inflammatory substances to the circulation and may therefore decrease the risk for endotoxemia (low-grade inflammation) and associated diseases.

Selcis BioPharma is developing a technology where SCFAs can be delivered to the colon.

Selcis Biopharma website

 

Selcis Biopharma

Develops a technology where SCFA´s can be delivered to the colon and potentially prevent or restore gut homeostasis.

Founded by Olov Sterner, Margareta Nyman, Martin Johansson and Carl-Magnus Andersson.

 

Portfolio company since 2020.

Portfolio Manager: christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78